• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Recall of Tandem Diabetes Care insulin pump app software is Class I, more than 200 injuries reported

May 9, 2024 By Sean Whooley

Tandem Diabetes Care t_slim X2 automated insulin pump Abbott FreeStyle Libre 2 Plus
t:slim X2 Insulin Pump from Tandem Diabetes Care with Abbott’s Freestyle Libre 2 Plus sensor integration now available in the United States. [Image courtesy of Abbott/Tandem Diabetes Care]
The FDA labeled a recall of a Tandem Diabetes Care (Nasdaq:TNDM) automated insulin delivery app’s software Class I, the most serious kind.

This recall constitutes a correction, not a product removal.

Tandem recalled Version 2.7 of the Apple iOS t:connect mobile app used in conjunction with the t:slim X2 pump with Control-IQ technology. It initiated the recall on March 18, 2024, with affected devices distributed between Feb. 12, 2024, and March 13, 2024. In total, the recall extends to 85,863 devices in the U.S.

According to an FDA notice, Tandem recalled the software version because of an issue that may cause the mobile app to crash and be automatically relaunched by the iOS operating system. This cycle intermittently repeats, which leads to excessive Bluetooth communication. That may result in pump battery drain, potentially leading to the pump shutting down sooner than typically expected.

Pump shutdown could cause insulin delivery to suspend, which may lead to an under-delivery of insulin. That, in turn, could result in hyperglycemia or diabetic ketoacidosis, a potentially life-threatening condition due to high blood sugars and lack of insulin.

Tandem received reports of 224 injuries as of April 15, 2024, with no deaths reported to date.

Pump shutdown will cause insulin delivery to suspend, which could lead to an under-delivery of insulin and may result in hyperglycemia or even diabetic ketoacidosis, which can be a life-threatening condition due to high blood sugars and lack of insulin.

t:slim X2, an automated insulin delivery system, utilizes Control-IQ technology that predicts glucose levels every 30 minutes into the future. It automatically adjusts insulin delivery every five minutes based on CGM readings. The technology can also deliver automatic correction boluses (up to one per hour) to help prevent hyperglycemia.

The iOS app works with the pump and Control-IQ software and can provide a method of viewing pump information, plus limited control of the pump.

Tandem instructed customers to update the mobile app to version 2.7.1 or later, available in the Apple App Store. Users should monitor their pump battery level closely to help prevent pump shutdown. They should also begin charging the device after the first low battery alert.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance, Technology Tagged With: FDA, Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS